Technical Analysis for ONCE - Spark Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 100.52 0.48% 0.48
ONCE closed down 0.94 percent on Friday, October 18, 2019, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ONCE trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 98.62%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 98.62%
Multiple of Ten Bullish Other 98.62%
Overbought Stochastic Strength 98.62%
Down 3 Days in a Row Weakness 98.62%
Earnings Movers Other 97.52%
Multiple of Ten Bullish Other 97.52%
Weak + Overbought Other 97.52%
Inside Day Range Contraction 97.52%
Overbought Stochastic Strength 97.52%

Older signals for ONCE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company is developing SPK-RPE65, which is in Phase III clinical trial for the treatment of inherited retinal dystrophies, a group of rare blinding conditions caused by non-sex linked, or autosomal recessive, mutations in the RPE65 gene. It is also developing SPK-CHM for the treatment of choroideremia; and preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases, as well as a pipeline of product candidates targeting rare blinding conditions. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B; and development and manufacturing collaboration with Genable Technologies Limited for the manufacture and provision of development advice in the development of Genable's therapeutic product candidate, GT038, to treat rhodopsin-linked autosomal dominant retinitis pigmentosa. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.
Biology Emerging Technologies Gene Therapy Molecular Biology Medical Genetics Blindness Neurodegenerative Diseases Retinitis Pigmentosa Genetic Diseases Gene Delivery Treatment Of Hemophilia Gene Therapy Products Hemophilia A Choroideremia Genetic Disorder Hemophilia B
Is ONCE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 114.2
52 Week Low 34.53
Average Volume 425,182
200-Day Moving Average 94.9505
50-Day Moving Average 99.9888
20-Day Moving Average 98.4915
10-Day Moving Average 98.866
Average True Range 2.0062
ADX 17.5
+DI 20.7174
-DI 15.1268
Chandelier Exit (Long, 3 ATRs ) 97.9814
Chandelier Exit (Short, 3 ATRs ) 101.9386
Upper Bollinger Band 101.8444
Lower Bollinger Band 95.1386
Percent B (%b) 0.73
BandWidth 6.808506
MACD Line -0.1504
MACD Signal Line -0.537
MACD Histogram 0.3866
Fundamentals Value
Market Cap 3.13 Billion
Num Shares 31.3 Million
EPS -6.39
Price-to-Earnings (P/E) Ratio -15.66
Price-to-Sales 124.29
Price-to-Book 11.08
PEG Ratio -0.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 102.25
Resistance 3 (R3) 102.45 101.92 101.88
Resistance 2 (R2) 101.92 101.36 101.82 101.75
Resistance 1 (R1) 100.98 101.01 100.72 100.78 101.63
Pivot Point 100.45 100.45 100.32 100.35 100.45
Support 1 (S1) 99.51 99.89 99.25 99.31 98.45
Support 2 (S2) 98.98 99.54 98.88 98.33
Support 3 (S3) 98.04 98.98 98.20
Support 4 (S4) 97.84